BRPI0516219A - composto de carboestirila - Google Patents

composto de carboestirila

Info

Publication number
BRPI0516219A
BRPI0516219A BRPI0516219-0A BRPI0516219A BRPI0516219A BR PI0516219 A BRPI0516219 A BR PI0516219A BR PI0516219 A BRPI0516219 A BR PI0516219A BR PI0516219 A BRPI0516219 A BR PI0516219A
Authority
BR
Brazil
Prior art keywords
hydrogen atom
carbostyril
diseases
bond
compound
Prior art date
Application number
BRPI0516219-0A
Other languages
English (en)
Inventor
Takahito Yamauchi
Tomoichi Shinohara
Kunio Oshima
Chiharu Kitajima
Hitoshi Nagao
Tae Fukushima
Takahiro Tomoyasu
Hironobu Ishiyama
Kazuhide Ohta
Masaaki Takano
Takumi Sumida
Takeshi Kuroda
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0516219A publication Critical patent/BRPI0516219A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPOSTO DE CARBOESTIRILA. A presente invenção fornece um composto de carboestirila representado pela Fórmula Geral (1) ou um sal deste, em que A é uma ligação direta, um grupo de alquileno inferior, ou um grupo de alquilideno inferior; X é um átomo de oxigênio ou um átomo de enxofre; R~ 4~ e R~ 5~ cada qual representa um átomo de hidrogênio; a ligação entre as posições 3 e 4 do esqueleto de carboestirila é uma ligação simples ou uma ligação dupla; R¹ é um átomo de hidrogênio, etc; R² é um átomo de hidrogênio, etc; e R³ é um átomo de hidrogênio, etc. O composto de carboestirila ou sal deste da presente invenção induz a produção de TFF e desse modo é utilizável para o tratamento e/ou prevenção de distúrbios tais como doenças do trato alimentar, doenças orais, doenças do trato respiratório superior, doenças do trato respiratório, doenças de olho, cânceres e ferimentos.
BRPI0516219-0A 2004-09-28 2005-09-26 composto de carboestirila BRPI0516219A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004282814 2004-09-28
PCT/JP2005/018217 WO2006035954A1 (en) 2004-09-28 2005-09-26 Carbostyril compound

Publications (1)

Publication Number Publication Date
BRPI0516219A true BRPI0516219A (pt) 2008-08-26

Family

ID=36119093

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516219-0A BRPI0516219A (pt) 2004-09-28 2005-09-26 composto de carboestirila

Country Status (16)

Country Link
US (2) US7777038B2 (pt)
EP (2) EP2426128A1 (pt)
JP (1) JP3906471B1 (pt)
KR (2) KR100840465B1 (pt)
CN (1) CN101068810B (pt)
AR (1) AR055193A1 (pt)
AU (2) AU2005288080B2 (pt)
BR (1) BRPI0516219A (pt)
CA (1) CA2580811C (pt)
ES (1) ES2393197T3 (pt)
IL (2) IL181630A0 (pt)
MX (1) MX2007003735A (pt)
RU (2) RU2430920C2 (pt)
TW (1) TWI353353B (pt)
WO (1) WO2006035954A1 (pt)
ZA (1) ZA200702228B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005288080B2 (en) * 2004-09-28 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
EP1900732A4 (en) * 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
JP2009537571A (ja) * 2006-05-22 2009-10-29 メルク フロスト カナダ リミテツド ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしての環状アミン誘導体
CA2657114A1 (en) * 2006-07-20 2008-01-24 Otsuka Pharmaceutical Co., Ltd. Nf-.kappa.b inhibitor
US8163779B2 (en) * 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
KR101537830B1 (ko) 2007-09-14 2015-07-17 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 고혈압 치료용 티아졸리딘디온 유사체
KR20120107493A (ko) 2009-12-15 2012-10-02 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
BR112014030412A2 (pt) 2012-06-14 2017-06-27 Basf Se método para combater ou controlar pragas, método para proteger culturas, compostos, processo para a preparação de compostos, uso de um composto, composição agrícola ou veterinária e semente.
RU2523387C1 (ru) * 2013-03-19 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ 6-[(4-МЕТИЛ-I-1-ПИПЕРАЗИНИЛ)МЕТИЛ]-ИНДОЛО[1',7':1,2,3]ПИРРОЛО[3',4':6,7]АЗЕПИНО[4,5-b]ИНДОЛ-1,3(2Н,10 Н)-ДИОНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВОГО СРЕДСТВА
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
HUE041546T2 (hu) * 2014-01-09 2019-05-28 Orion Corp Biciklusos heterociklusos származékvegyületek mint bromo doméninhibitorok
EP3212197A4 (en) 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
GB2532990A (en) 2014-12-05 2016-06-08 Schlumberger Holdings Corrosion inhibition
GB2543498A (en) 2015-10-19 2017-04-26 Schlumberger Holdings Corrosion inhibition
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN108948029A (zh) * 2017-05-27 2018-12-07 华中科技大学 菲啶酮衍生物及其合成方法和抗肿瘤应用
US10324266B1 (en) * 2018-01-12 2019-06-18 Vinay Advani LED light projection with multiple lenses
CN108864072B (zh) * 2018-08-01 2021-03-23 西南大学 香豆素噻二酮类化合物及其制备方法和应用
CN118206542B (zh) * 2023-03-22 2025-06-27 沈阳药科大学 一种化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152905A (en) * 1961-02-09 1964-10-13 Minnesota Mining & Mfg Sensitizing methine dyes and intermediates, process for preparing same and photographic element containing these dyes
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
DE69232619T2 (de) 1991-02-14 2002-09-12 The General Hospital Corp., Charlestown Intestinale kleeblatt-proteine
KR20010099634A (ko) 1999-07-01 2001-11-09 할리 켈빈 비. 텔로머라제 저해제 및 그 사용 방법
EP1341817A2 (en) 2000-12-08 2003-09-10 Novo Nordisk A/S Tff peptides
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
AU2002237251A1 (en) 2000-12-22 2002-07-08 K.U. Leuven Research And Development A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
EP1401481A1 (en) 2001-06-14 2004-03-31 Novo Nordisk A/S Mucosal repair by tff dimer peptides
CA2460541A1 (en) * 2001-09-14 2003-04-03 Helle Birk Olsen Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
US20040214872A1 (en) * 2002-09-26 2004-10-28 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2004064860A1 (en) * 2003-01-17 2004-08-05 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
CN1205934C (zh) 2003-01-20 2005-06-15 鲁南制药股份有限公司 治疗高血脂症的组合物
AU2005288080B2 (en) * 2004-09-28 2011-10-13 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound

Also Published As

Publication number Publication date
EP2426128A1 (en) 2012-03-07
RU2430920C2 (ru) 2011-10-10
IL210756A0 (en) 2011-03-31
TW200616961A (en) 2006-06-01
CN101068810B (zh) 2011-02-09
MX2007003735A (es) 2007-04-23
WO2006035954A1 (en) 2006-04-06
KR100840465B1 (ko) 2008-06-20
EP1797082A1 (en) 2007-06-20
TWI353353B (en) 2011-12-01
ZA200702228B (en) 2009-06-24
KR100823414B1 (ko) 2008-04-17
EP1797082B1 (en) 2012-08-29
JP3906471B1 (ja) 2007-04-18
JP2007512220A (ja) 2007-05-17
US20070179173A1 (en) 2007-08-02
CA2580811C (en) 2014-04-08
CA2580811A1 (en) 2006-04-06
AU2005288080A1 (en) 2006-04-06
ES2393197T3 (es) 2012-12-19
HK1109901A1 (en) 2008-06-27
CN101068810A (zh) 2007-11-07
AU2005288080B2 (en) 2011-10-13
AU2011202454B2 (en) 2012-03-08
US8362252B2 (en) 2013-01-29
IL181630A0 (en) 2007-07-04
AR055193A1 (es) 2007-08-08
KR20070061902A (ko) 2007-06-14
RU2007116147A (ru) 2008-11-10
EP1797082A4 (en) 2009-09-23
US20100261705A1 (en) 2010-10-14
RU2011123036A (ru) 2012-12-20
AU2011202454A1 (en) 2011-06-16
KR20070072632A (ko) 2007-07-04
US7777038B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
BRPI0516219A (pt) composto de carboestirila
BR0311494A (pt) Novos indóis substituìdos
BR0312729A (pt) Novos derivados de indol-3-enxofre
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
BRPI0410711A (pt) novos compostos
NO20083710L (no) Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser
MA31314B1 (fr) Derives de pleuromutiline pour le traitement de maladies transmises par des microbes
DE60129806D1 (de) Neue bizyklische verbindungen
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MY141229A (en) Piperidine-benzenesulfonamide derivatives
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
IS2293B (is) Arýl sambrædd asapólýsýklísk efnasambönd
SI1696905T1 (sl) Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni
BRPI0414266A (pt) derivados de tiazolopiridina como ligandos receptores da adenosina
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
DE602006010776D1 (de) Piperazinylalkylpyrazol-Derivate zur Verwendung als selektive Calciumkanalblocker des T-Typs und Verfahren zu ihrer Herstellung
UA85707C2 (ru) Бензоксазины для лечения заболеваний дыхательных путей
BR0315846A (pt) Tratamento farmacológico para apnéia do sono
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
BRPI0407055A (pt) Derivados de isotiazol
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
ATE526967T1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
MX2007006357A (es) Pteridinas sustituidas para el tratamiento de enfermedades inflamatorias.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.